Document:

Exhibit 10.1

 

 

SETTLEMENT AND AMENDMENT AGREEMENT

 

 

This Settlement and Amendment Agreement
dated as of August 30, 2012 (this “Agreement”), by and among KIT digital, Inc., a Delaware corporation (the
“Company”), and the party listed as the Investor on the signature page hereto (“Investor”).
The Company and the Investor are referred to herein as the “Parties.” Capitalized terms used but not otherwise
defined herein shall have the respective meanings given to them in the Securities Purchase Agreement (as defined herein below).

 

WHEREAS, the Company and the Investor are
parties to that certain Securities Purchase Agreement, dated May 15, 2012 (the “Securities Purchase Agreement”)
pursuant to which, among other things, the Company issued to the Investor a warrant to purchase shares of common stock of the Company
(each warrant, a “Warrant”);

 

WHEREAS, the Company and the Investor have
a dispute regarding the First Adjustment Share Amount and the amount and timing of a cash settlement to be made under Section 1(b)(v)
of the Securities Purchase Agreement;

 

WHEREAS, Section 9(e) of the Securities
Purchase Agreement provides that the Securities Purchase Agreement may be amended by an instrument signed by the Company and the
Required Holders, but this Agreement will not be effective until each of the other investors under the Securities Purchase Agreement
(the “Other Investors”) sign an Other Agreement (as defined below);

 

WHEREAS, Section 9 of the Warrants provides
that the Warrants may be amended if the Company has obtained the written consent of the Required Holders, but this Agreement will
not be effective until each of the Other Investors sign an Other Agreement; and

 

WHEREAS, the Parties desire to resolve in
writing all differences they have with respect to the Securities Purchase Agreement and the Warrants as to the payment of the Adjustment
Shares and cash amounts related thereto.

 

NOW, THEREFORE, in
consideration of the premises and mutual covenants and agreements set forth herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties hereto hereby agree as follows:

 

1.         Effective
Time. This Agreement shall be deemed effective upon the latest to occur of (a) the date the Company and the Investor shall
have executed and delivered this Agreement, (b) the date the Company and each of the Other Investors shall have executed and delivered
an agreement in substance identical to this Agreement (other than with respect to
legal fee reimbursement by the Company) (collectively, the “Other Agreements”),
(c) the delivery of the first Cash Payment to the Investor by the Company, as contemplated in Section 5 hereof, and (d) the date
the Company shall have paid the Legal Fee Payment (as defined below) to Schulte Roth & Zabel LLP (the “Effective Time”).
Investor hereby consents for all purposes of the Transaction Documents to all the terms and conditions of this Agreement and the
transactions contemplated hereby.

    	 

    	 

    
 

 

2.         Investor’s
Representations and Warranties. The Investor represents and warrants to the Company with respect to only itself that, as of
the date hereof and as of the Effective Time:

 

(i)         Validity;
Enforcement. This Agreement has been duly and validly authorized, executed and delivered on behalf of the Investor and constitutes
the legal, valid and binding obligations of the Investor enforceable against the Investor in accordance with its terms, except
as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and
remedies.

 

(ii)         No
Conflicts. The execution, delivery and performance by the Investor of this Agreement and the consummation by the Investor of
the transactions contemplated hereby will not (x) result in a violation of the organizational documents of the Investor, (y) conflict
with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to
others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the
Investor is a party, or (z) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and
state securities laws) applicable to the Investor, except in the case of clauses (y) and (z) above, for such conflicts, defaults,
rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect
on the ability of the Investor to perform its obligations hereunder.

 

3.         Company’s
Representations and Warranties. The Company represents and warrants to the Investor that, as of the date hereof and as of the
Effective Time:

 

(i)         Organization
and Qualification. Each of the Company and its “Subsidiaries” (which for purposes of this Agreement means
any entity in which the Company, directly or indirectly, owns any of the capital stock or holds an equity or similar interest)
are entities duly organized and validly existing in good standing under the laws of the jurisdiction in which they are formed,
and have the requisite power and authorization to own their properties and to carry on their business as now being conducted. Each
of the Company and its Subsidiaries is duly qualified as a foreign entity to do business and is in good standing in every jurisdiction
in which its ownership of property or the nature of the business conducted by it makes such qualification necessary, except to
the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a Material Adverse
Effect. As used in this Agreement, “Material Adverse Effect” means any material adverse effect on the business,
properties, assets, operations, results of operations, condition (financial or otherwise) or prospects of the Company and its Subsidiaries,
taken as a whole, or on the transactions contemplated hereby or on the other Transaction Documents or by the agreements and instruments
to be entered into in connection herewith or therewith, or on the authority or ability of the Company to perform its obligations
under the Transaction Documents.

    	 

    	 

    
 

 

(ii)         Authorization;
Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement. The execution and delivery of this Agreement by the Company and the consummation by the Company of the transactions
contemplated hereby have been duly authorized by the Company’s Board of Directors and no further filing, consent, or authorization
is required by the Company, its Board of Directors or its stockholders. This Agreement has been duly executed and delivered by
the Company, and constitutes the legal, valid and binding obligations of the Company, enforceable against the Company in accordance
with their respective terms, except as such enforceability may be limited by general principles of equity, applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable
creditors’ rights and remedies, or limits on indemnification under applicable federal securities laws.

 

(iii)         No
Conflicts. The execution, delivery and performance this Agreement by the Company and the consummation by the Company of the
transactions contemplated hereby will not (i) result in a violation of any memorandum of association, certificate of incorporation,
certificate of formation, any certificate of designations or other constituent documents of the Company or any of its Subsidiaries,
any capital stock of the Company or any of its Subsidiaries or the articles of association or bylaws of the Company or any of its
Subsidiaries or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become
a default) in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation of, any material
agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, or (iii) result in a violation of
any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and the rules
and regulations of The NASDAQ Global Select Market (the “Principal Market”) and applicable laws of the State
of Delaware and any other state laws) applicable to the Company or any of its Subsidiaries or by which any property or asset of
the Company or any of its Subsidiaries is bound or affected.

 

(iv)         Consents.
Neither the Company nor any of its Subsidiaries is required to obtain any consent, authorization or order of, or make any filing
or registration with, any court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for
it to execute, deliver or perform any of its obligations under or contemplated by this Agreement, in each case in accordance with
the terms hereof. All consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant
to the preceding sentence have been obtained or effected on or prior to the date hereof (or in the case of filings, will be made
timely after the date hereof), and the Company is unaware of any facts or circumstances that might prevent the Company from obtaining
or effecting any of the registration, application or filings pursuant to the preceding sentence. The Company is not in violation
of the listing requirements of the Principal Market and has no knowledge of any facts that would reasonably lead to delisting or
suspension of the Common Stock in the foreseeable future. The issuance by the Company of the Securities shall not have the effect
of delisting or suspending the Common Stock from the Principal Market.

    	 

    	 

    
 

 

(v)         No
Undisclosed Event. The Company represents that, as of the date hereof, no material event or circumstance has occurred which
would be required to be publicly disclosed or announced on a Current Report on Form 8-K, either as of the date hereof or solely
with the passage of time by the Company but which has not yet been so publicly announced or disclosed.

 

4.         Payment.
Company agrees to pay to the Investor an aggregate amount of $_________ [NOTE - $[4,450,000] to all Investors] (the “Cash
Payment”). [NOTE - The amount payable to each Investor shall be in proportion to such Investor’s total investment
amount under the Securities Purchase Agreement as set forth in the Schedule of Buyers attached thereto]. Fifty percent (50%) of
such amount shall be paid by wire transfer of immediately available funds within one Business Day of the date hereof to an account
designated in writing by Investor. The remaining fifty percent (50%) of such amount shall be paid by wire transfer of immediately
available funds on October 15, 2012 to an account designated in writing by Investor. Notwithstanding anything to the contrary contained
herein, if the Company shall fail to pay to the Investor the Cash Payment in full on or prior to October 15, 2012, unless waived
in writing by the Investor in its sole discretion, effective as of 12:01 am Eastern time on October 16, 2012, the provisions of
Sections 5, 6, 7 and 11 hereof shall be automatically terminated and cancelled and shall be deemed to be void ab initio.

 

5.         Amendments
to the Securities Purchase Agreement. Upon the Effective Time, the Investor, (who together with Other Investors constitute
the Required Holders), and the Company hereby amend the Securities Purchase Agreement pursuant to Section 9(e) thereof as follows:

 

a)         The Parties agree
and acknowledge that no further Adjustment Shares shall be required to be issued under the Securities Purchase Agreement and no
cash amounts shall be required to be paid in respect of any Adjustment Shares or failure to issue any such Adjustment Shares. In
furtherance of the foregoing, the Parties agree and acknowledge that there shall be no “Second Adjustment Date,” “Second
Adjustment Price,” “Second Adjustment Share Amount,” “Third Adjustment Date,” “Third Adjustment
Price,” and “Third Adjustment Share Amount.” Accordingly, the Securities Purchase Agreement is hereby amended,
from and after the date hereof, such that Section 1(b) and Section 1(c) of the Securities Purchase Agreement are hereby deleted
in their entirety.

 

b)         Section 4(o)(ii)
of the Securities Purchase Agreement is hereby deleted in its entirety and replaced with “[Intentionally Omitted]”.

 

c)         The first sentence
of Section 4(o)(iii) of the Securities Purchase Agreement is hereby amended in its entirety so that it reads: “From and after
the date hereof until the eighteen (18) month anniversary of the Closing Date, the Company will not, directly or indirectly, effect
any Subsequent Placement unless the Company shall have first complied with this Section 4(o)(iii).” The term “Subsequent
Placement” shall have the same meaning as set forth in the Securities Purchase Agreement immediately prior to the Effective
Time.

    	 

    	 

    
 

 

d)         The definition
of Stockholder Meeting Deadline in Section 4(q) of the Securities Purchase Agreement is hereby amended in its entirety so that
it reads: “...as promptly as commercially appropriate as determined in the good faith business judgment of the Company’s
Board of Directors, but in no event later than December 15, 2012”.

 

6.         Warrant Amendments.
Upon the Effective Time, the Investor executing this Agreement (who together with Other Investors constitute all holders of Warrants)
and the Company hereby amend all of the issued and outstanding Warrants pursuant to Section 9 thereof as follows (with capitalized
terms used herein as defined in the Warrants):

 

Section 4 of the Warrants
shall be amended by adding thereto a new paragaph (d) as follows:

 

“(d) In the event
that a Fundamental Transaction is consummated whereby the Successor Entity (or its Parent) in such Fundamental Transaction acquires
100% of the equity of the Company not already owned by it or its affiliates solely through the payment of cash consideration, then
notwithstanding anything to the contrary in this Section 4, the Company shall be permitted to effect such Fundamental Transaction,
and the Holder shall only have the right, in connection with such Fundamental Transaction, to elect (the “Fundamental
Transaction Election”) to receive at the consummation of such Fundamental Transaction either (x) all consideration to
be received by a holder of the number of shares of Common Stock for which this Warrant is then exercisable (without giving effect
to any limitations or restrictions on exercise herein) less the aggregate Exercise Price under this Warrant for such number of
shares of Common Stock or (y) the Black Scholes Value of the remaining unexercised portion of this Warrant (without giving effect
to any limitations or restrictions on exercise herein), such Fundamental Transaction Election to be made by the Holder hereof by
written notice to the Company not less than five (5) days prior to the consummation of such Fundamental Transaction (the “Election
Time”). If the Holder fails to deliver any such notice by the Election Time, the Holder shall be deemed to have elected
to receive the Black-Scholes Value of this Warrant contemplated in clause (y) above. Such written notice shall contain wire transfer
instructions for payment of such amounts due under this paragraph (or if no notice is provided and an election is deemed to have
been made to receive the Black Scholes Value the wire transfer instructions provided in connection with this Agreement shall be
used or, at the request of the Company, the Holder shall be required to provide wire instructions for use for the payment of the
Black Scholes Value at the consummation of such Fundamental Transaction). The Company shall have the obligation to pay, or cause
to be paid, all amounts contemplated to be paid to the Holder under this paragraph (d) simultaneously with the consummation of
the applicable Fundamental Transaction contemplated above. Upon the consummation of such Fundamental Transaction and the Holder’s
receipt of all payments contemplated to be paid to the Holder under this paragraph (d), the Warrant shall cease to be outstanding.
Notwithstanding anything to the contrary contained herein, the provisions of this paragraph (d) shall be subject to the requirement
that the Fundamental Transaction be consummated on the same terms as in effect at the Election Time. If the Fundamental Transaction
is consummated on terms that are different from the terms of such Fundamental Transaction prevailing at the Election Time, (i)
the Company shall so notify the Holder in writing promptly but in no event later than five (5) Business Days immediately prior
to the consummation of such Fundamental Transaction and (ii) the Holder shall have the right to submit another Fundamental Transaction
Election by written notice to the Company not later than one (1) Business Day prior to the consummation of such amended Fundamental
Transaction; provided, however, that in the event that the terms of such Fundamental Transaction change after the
Election Time such that such Fundamental Transaction no longer provides for the acquisition of 100% of the equity of the Company
as aforesaid and/or the consideration to be paid upon consummation of such Fundamental Transaction includes consideration other
than cash, the provisions of this paragraph (d) shall no longer apply to such Fundamental Transaction and the Holder shall have
all rights otherwise set forth in Section 4 hereof.”

    	 

    	 

    
 

 

In addition, the definition of “Fundamental Transaction”
set forth in Section 17(l) of the Warrants is hereby amended to add the following sentence to the end of such definition: “Notwithstanding
anything to the contrary contained in the definition of Fundamental Transaction, a consolidation, merger, sale, assignment, transfer,
conveyance or other disposition by a Subsidiary that would otherwise be covered by clause (A)(i) or (A)(ii) of the definition of
Fundamental Transaction where the consideration in such Fundamental Transaction is solely cash (and/or, in the case of an asset
sale transaction, assumption of liabilities) shall not constitute a Fundamental Transaction so long as (i) the consummation of
any such transaction shall have occurred after August 30, 2012 and on or prior to February 27, 2014, (ii) the aggregate gross revenues
represented by (x) the Subsidiaries and assets of such Subsidiaries that are subject to all such transactions and (y) any other
consolidation, merger, sale, assignment, transfer, conveyance or other disposition of a Subsidiary or by a Subsidiary (but it is
understood and agreed that a sale, assignment, transfer, conveyance or disposition by a Subsidiary of products in
the ordinary course of business operations consistent with past practices, which products are regularly sold, assigned,
transferred, conveyed or disposed of (and non-exclusive licenses with respect to such products) shall
not be taken into account for purposes of this clause (y))
on or after August 30, 2012, are no more than $36 million in the aggregate for all such transactions calculated based on
the gross revenues for any applicable Subsidiary for the twelve month period ending on June 30, 2012 (assuming no restatements
of the financial statements for such period, otherwise in the event of a restatement such numbers shall be recalculated accordingly),
as set forth in audited financial statements prepared in each case in accordance with US generally acceptable accounting principles,
consistently applied ("GAAP"); provided, that the foregoing shall not constitute an exception to a Fundamental
Transaction for any transaction or series of transactions that result in the transfer (whether by any of the methods contemplate
in clauses (A)(i) or (A)(ii) of the definition of Fundamental Transaction or a combination thereof) of any Subsidiary and/or assets
of any Subsidiary representing more than a majority of the consolidated gross revenues of the Company and all of its Subsidiaries
based on the gross revenues from the trailing twelve month period ending on last date of the most recent income statement publicly
disclosed in the Company's most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K prior to such transaction, in
each case prepared in accordance with GAAP). For the avoidance of doubt: (i) the provisions in the foregoing sentence shall no
longer be applicable with respect to any transaction consummated after February 27, 2014, (ii) the provisions in the foregoing
sentence shall not create any exceptions to the definition of Fundamental Transaction other than as explicitly set forth in the
foregoing sentence, and (iii) any attempt to directly or indirectly structure a transaction or series of transactions to circumvent
the intent of the forgoing provision shall be null and void.”

 

7.         General Amendment.
In the event the Company consummates a Fundamental Transaction whereby the Successor Entity (or its Parent) in such Fundamental
Transaction effects the acquisition of 100% of the equity of the Company by paying only cash consideration and the Company and
the Successor Entity (or its Parent), as applicable, have complied in all respects with all provisions governing such Fundamental
Transactions pursuant to Section 4 of the Warrants, the following provisions shall no longer apply after the consummation of such
Fundamental Transaction: (i) Section 4(g) of the Securities Purchase Agreement requiring the Company to maintain the listing of
the Common Stock and to list the Adjustment Shares and the Warrant Shares on an Eligible Market and (ii) Section 8 of the Registration
Rights Agreement requiring the Company to file periodic reports in accordance with the 1934 Act.

    	 

    	 

    
 

 

8.         Acknowledgment.
Other than as explicitly amended in this Agreement, the provisions of the Transaction Documents shall remain in full force and
effect.

 

9.         Fees.
Within one Business Day following execution of this Agreement, the Company hereby agrees to reimburse the Investor for its legal
fees and expenses up to a maximum aggregate amount of $65,000 (the “Legal Fee Payment”) (in connection with
the preparation, review and negotiation of this Agreement and all other agreements entered into with other investors substantially
similar to this Agreement and entered into substantially simultaneously with this Agreement in connection with transactions contemplated
thereby and any prior unpaid and outstanding legal fees and expenses incurred by Schulte Roth & Zabel LLP to date with respect
to the Transaction Documents or any proposed amendments or waivers thereto), by paying any such amount to Schulte Roth & Zabel
LLP by wire transfer of immediately available funds in accordance with the written instructions of Schulte Roth & Zabel LLP.
Except as otherwise set forth above, each party shall pay the fees and expenses of its advisers, counsel, accountants and other
experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, review, execution, delivery
and performance of this Agreement.

 

10.         Disclosure
of Transactions. On or before 9:30 a.m., New York City time, on August 30, 2012, the Company shall file a Current Report on
Form 8-K describing the terms of the transactions contemplated by this Agreement and the Other Agreements in the form required
by the 1934 Act and attaching a form of this Agreement (including all attachments, the “8-K Filing”). From and
after the filing of the 8-K Filing with the SEC, the Investor shall not be in possession of any material, nonpublic information
received from the Company, any of its Subsidiaries or any of their respective officers, directors, employees or agents, that is
not disclosed in the 8-K Filing. The Company shall not, and shall cause each of its Subsidiaries and its and each of their respective
officers, directors, employees and agents, not to, provide the undersigned with any material, nonpublic information regarding the
Company or any of its Subsidiaries from and after the filing of the 8-K Filing with the SEC without the express prior written consent
of the Investor.

 

11.         Settlement
and Complete Agreement. Effective upon the Effective Time, the Company and the undersigned Investor agree that the provisions
of this Agreement are in full settlement of any claims for, or relating to, payment of Adjustment Shares (or cash in lieu thereof
as contemplated by Section 1(b)(v) of the Securities Purchase Agreement, whether due as interest or a penalty payment), that may
be issued under the Securities Purchase Agreement and that, upon consummation of the transactions contemplated by this Agreement,
no further Adjustment Shares (or cash in lieu thereof, or other cash with respect to the Adjustment Shares or cash in lieu thereof)
are issuable under the Securities Purchase Agreement and that Investor shall have no claims, rights or causes of action in any
way related thereto or for any purported breach related thereto (the “Existing Claims”). The foregoing release
applies only to the Existing Claims and extends to no other contract, debt, account, agreement, obligations, cause of action, liability
or undertaking by and between the parties, which, if existing, shall survive this release and remain in full force and effect and
undisturbed by this specific release. In entering into this Agreement, each Party acknowledges that it has received adequate information
to enter into this Agreement, that it has relied solely on the terms and conditions set forth herein in entering into this Agreement,
that it has not relied on any promise, representation or warranty, express or implied, not contained in this Agreement and that
it has been represented by counsel in connection with this Agreement. The provisions of the Agreement shall be interpreted in a
manner to effect the intent of the Parties.

    	 

    	 

    
 

 

12.         Most Favored
Nation. The Company hereby represents and warrants as of the date hereof and covenants and agrees from and after the date hereof
that none of the terms offered to any Other Investor with respect to any amendment, settlement or waiver (each a “Settlement
Document”) relating to the Exiting Claims, is or will be more favorable to such Person (other than with respect to legal
fee reimbursement) than those of the Investor and this Agreement shall be, without any further action by the Investor or the Company,
deemed amended and modified in an economically and legally equivalent manner such that the Investor shall receive the benefit of
the more favorable terms contained in such Settlement Document. Notwithstanding the foregoing, the Company agrees, at its expense,
to take such other actions (such as entering into amendments to the Transaction Documents) as the Investor may reasonably request
to further effectuate the foregoing.

 

13.         Notices.
Notices hereunder shall be delivered in accordance with the Section 9(f) of the Securities Purchase Agreement.

 

14.         Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed
by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule
(whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions
other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each
party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service
shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in
any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE,
AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS
AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

    	 

    	 

    
 

 

15.         Entire Agreement;
Interpretation. This Agreement constitutes the full and entire understanding and agreement among the Parties with regard to
the subject matter hereof, and supersedes all prior agreements with respect to the subject matter hereof. The titles and subtitles
used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

 

16.         Invalidity.
If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the
broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect
the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without
material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or
unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations
of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will
endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s),
the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

17.         Amendments.
This Agreement may be modified, amended or otherwise changed only in a writing signed by the Company and the Investors constituting
Required Holders.

 

18.         Successors.
This Agreement shall bind the successors and permitted assigns of the Parties, and inure to the benefit of any successor or permitted
assign of any of the parties; provided, however, that no party may assign this Agreement without the prior written consent of the
other Parties. No provision of this Agreement is intended to confer any rights, benefits, remedies, obligations, or liabilities
hereunder upon any person other than the Parties hereto and their respective successors and assigns.

 

19.         Counterparts.
This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the
signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each Party hereto shall
have received a counterpart hereof signed by the other Parties hereto. Counterparts delivered by electronic transmission shall
be deemed to be originally signed counterparts.

 

20.         Termination.
In the event that the Effective Time shall not have occurred on or prior to the second Business Day following the date hereof because
of any act or omission by the Company, the Investor shall have the option to terminate this Agreement by delivering a written notice
to that effect to the Company without any liability to the Investor. Upon delivery of any such notice, subject to the Company’s
obligation to reimburse the Investor for its legal fees pursuant to Section 9 hereof (which obligation shall survive such termination),
all provisions of this Agreement shall be void ab initio.

 

 

[Signature page follows]

    	 

    	 

    

IN WITNESS WHEREOF,
Investor and the Company have caused their respective signature page to this Settlement and Amendment Agreement to be duly executed
as of the date first written above.

 

	 	COMPANY:
	 	 
	 	KIT DIGITAL, INC.
	 	 
	 	By:	
	 	 	Fabrice Hamaide
	 	 	Chief Financial Officer

 

 

 

 

 

 

[Signature Page to Settlement and Amendment
Agreement]

    	 

    	 

    

 

 

	 	INVESTOR:
	 	 
	 	 
	 	By:	 
	 	 	Name: 
	 	 	Title:

 

[Signature Page to Settlement and Amendment
Agreement]Exhibit 10.1

 

 

 

August 20, 2012

 

  

Eric Rowinsky MD

15 Central Park West, Apt 703C

New York, NY 10023

 

Dear Eric:

 

This letter is to confirm our mutual understanding with respect
to the terms and conditions under which you agree to provide Navidea Biopharmaceuticals, Inc. (hereinafter referred to as “Navidea”)
with Consulting Services during the period from August 1, 2012 through January 31, 2013 (the “Consulting Period”).

 

As used herein, the term “Consulting Services” shall
mean carrying out the following job duties, which shall include, but shall not be limited to:

		1.	Medical, clinical development, strategic support to business development objectives focusing on new product assessments for
in-licensing, M&A prospects and territory deals pertaining to existing products;

		2.	Clinical development support with a particular focus Lymphoseek development (Europe/ROW, current usage of sentinel node
mapping/product in melanoma and breast cancer; expansion of studies into head and neck, GI, other tumor types), RIGS development
and new products;

		3.	Assisting with formation of the company's Scientific/Medical Advisory Board and ad hoc medical advisory groups (e.g. Key Opinion
Leader cultivation); and

		4.	Assisting with investor relations, roadshows, presentations and financings.

 

In performing Consulting Services for Navidea, you will report
directly to Mark Pykett. You agree that the Consulting Services will be performed in a workmanlike manner, with professional diligence
and skill, and in accordance with reasonable commercial or professional standards.

 

In exchange for performing the Consulting Services, Navidea
agrees to grant you thirteen thousand seven hundred sixty-four (13,764) options to purchase Navidea common stock at an exercise
price of $3.61 per share for performing the Consulting Services. The options will be governed by a separate option grant agreement
and will vest one sixth per month for each month this Consulting Services Agreement is in effect. This option grant is intended
to represent payment for an average of two (2) days per month during the six month period. Consulting Services rendered in excess
of four days in any given month must be pre-approved by the Company prior to undertaking said services. In the event that Consulting
Services total more than twelve (12) days during the Consulting Period, the Company agrees to determine compensation to Consultant
for authorized services at a rate consistent with that agreed to above, payable in cash or stock options, at the option of the
Company.

 

It is understood and agreed that Navidea will stipulate the
places and locations where you will provide Consulting Services and, where this requires you to travel away from the metropolitan
area of your regular place of residence or business, Navidea will reimburse you for the reasonable travel and living expenses actually
incurred by you, upon submission by you and approval by Navidea of an itemized account of the expenses for which reimbursement
is sought, along with receipts for expenses greater than $25. However, travel time will not be considered to be time spent in the
service of Navidea in a Consulting capacity.

 

    	 

    	 

    

 

Eric Rowinsky, MD

August 20, 2012

Page 2 of 3

 

During the Consulting Period, either through the performance
of Consulting Services or otherwise, you may acquire proprietary and confidential information (herein “Information”)
with respect to the business and research activities of Navidea. You agree to keep confidential such Information and not to divulge
any such Information to others. Specifically, you agree that you will not directly or indirectly, publish or disclose to others,
except with the written consent of Navidea, any Information, data or methods of manufacture received or obtained from Navidea,
nor use such Information in any way, commercially or otherwise, except in performing the Consulting Services. This obligation of
confidentiality and non-use shall continue until two (2) years after the expiration of this Agreement, but shall not apply to Information
which (i) becomes a matter of public knowledge through no fault of yours; (ii) is rightfully received by you from a third party
without restriction on disclosure; (iii) is independently developed by you without the use of Information; or (iv) is rightfully
in your possession prior to its disclosure to you by the Navidea.

 

You hereby irrevocably transfer and assign to Navidea without
further compensation, any and all of your right, title and interest in and to all designs, ideas, discoveries, inventions, products,
computer programs, source code, procedures, improvements, documents, information and materials made, conceived or developed by
you alone or with others, which result from or relate to the Consulting Services (“Work Product”), including, but not
limited to, all copyrightable works and copyrights, patent rights, trade secrets and trademarks, any right to claim authorship
of Work Product, or any right to object to any distortion or other modification of Work Product by Navidea. Notwithstanding this
assignment and transfer, if any Work Product incorporates or relies upon works developed by you prior to the effective date of
this Agreement, you shall continue to retain ownership of thereof, but you hereby license Navidea to use, or have third parties
use on Navidea’s behalf, such preexisting works as is reasonably required to fully exploit the Consulting Services performed
hereunder. You agree, during and for one year following the term of the Agreement to: (i) disclose promptly in writing to Navidea
all Work Product; and (ii) to sign and provide any and all documents and render any assistance that is reasonably necessary for
Navidea to obtain any patent, copyright, trademark or other protection for Work Product. In case any invention is described in
a patent application or is disclosed to third parties by you within one (1) year after the Consulting Services have been completed,
it shall be presumed that the invention was conceived or made during the period in which the Consulting Services were rendered,
and the invention will be assigned to Navidea as set forth in this Agreement, provided that the invention results from or relates
to the Consulting Services. If the invention was made by you prior to any association with Navidea or was made without the Information
or resources of Navidea, then you need not assign the invention to the Company as set forth herein.

 

At the expiration of this Agreement, you agree to promptly deliver
to Navidea all documents, notes, or other papers supplied to you by Navidea in connection with your Consulting Services, which
were in your possession and under your control during the time you provided your Consulting Services to Navidea. You agree that
you will not make or retain or give away any copies of such documents.

 

    	 

    	 

    

 

Eric Rowinsky, MD

August 20, 2012

Page 2 of 3

 

Either party may terminate this Agreement with ten (10) business
days’ prior written notice to the other. Early termination of this Agreement by Navidea shall not relieve Navidea of any
liability for payment of consulting fees that accrued prior to the date of termination of the Agreement, nor relieve you of any
obligations with respect to the confidentiality and non-use of Information, the transfer of rights in any Work Product, or the
return to Navidea of any documents, notes or other papers.

 

It is understood and agreed that your status shall be that of
an independent contractor and not that of an employee of Navidea, and you will not, therefore, be entitled to any of the benefits
available to employees of Navidea. It is further understood and agreed that no representations have been made to you by Navidea
that satisfactory performance of the Consulting Services described herein will lead to an offer of permanent employment with Navidea.

 

This Agreement shall be construed and governed by the laws of
the State of Ohio and adjudicated within the exclusive jurisdiction of the courts having jurisdiction over Franklin County, Ohio.

 

If the foregoing terms and conditions meet with your understanding
and approval, please show your acceptance and agreement by executing this letter in duplicate at the place indicated below and
returning one of the executed duplicates to us, whereupon this letter shall constitute the agreement between you and Navidea with
respect to your services in a consulting capacity.

 

Very truly yours,

 

Navidea Biopharmaceuticals, Inc.

 

 

	By: 	/s/ Mark, J. Pykett	 
	 	Mark J. Pykett       	 
	 	President and Chief Executive Officer	 

 

 

Accepted and agreed to:

 

 

	By:	/s/ Eric Rowinsky	 
	       	 	 
	Date:	8/27/12	 
	 	 	 
	SSN:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}]]